Company Overview - BioLineRx Ltd. is a clinical-stage biopharmaceutical company focused on developing life-changing therapies in oncology and rare diseases [4] - The company's first approved product is APHEXDA® (motixafortide), indicated for stem cell mobilization for autologous transplantation in multiple myeloma [4] Financial Results Announcement - BioLineRx will release its audited financial results for the year ended December 31, 2024, on March 31, 2025, before U.S. markets open [1] - A conference call will be held at 8:30 a.m. EDT featuring remarks by CEO Philip Serlin [2] Conference Call Details - To access the conference call, dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally [3] - A live webcast and replay will be available on the company's website, with a replay accessible approximately two hours after the live call [3]
BioLineRx to Report 2024 Annual Results on March 31, 2025